文献速递湿疹皮炎与荨麻疹

青少年湿疹患者使用润肤剂和外用糖皮质激素的情况:基于人群出生队列BAMSE的数据

Use of emollients and topical glucocorticoids among adolescents with eczema: data from the population-based birth cohort BAMSE.
PubMed 文献 · Br J Dermatol · 2018-06-21

基于瑞典人群出生队列BAMSE的3108名青少年问卷数据,10%报告过去一年有湿疹,其中73%为轻度、17%为中度、10%为重度。几乎所有患者使用润肤剂,55%报告使用外用糖皮质激素,性别间无显著差异。有当前湿疹症状者使用润肤剂和外用糖皮质激素的调整OR为5.95(95%CI 1.90-18.8),但湿疹严重程度与治疗使用无显著关联(调整OR 1.57,95%CI 0.58-4.25)。结论认为青少年湿疹患者存在治疗不足或完全未治疗。

要点

  • BAMSE队列中10%青少年报告过去一年有湿疹,其中73%为轻度、17%为中度、10%为重度(BESS评分)。
  • 55%报告使用外用糖皮质激素,性别间无显著差异;几乎所有患者使用润肤剂。
  • 有当前湿疹症状者使用润肤剂和外用糖皮质激素的调整OR为5.95(95%CI 1.90-18.8),但严重程度与治疗使用无显著关联(调整OR 1.57,95%CI 0.58-4.25)。

核心结论

  • 这项基于人群的研究表明,青少年湿疹患者存在治疗不足或完全未治疗,即使是重度湿疹患者也是如此。

研究设计与样本

  • 基于瑞典人群出生队列BAMSE的问卷调查研究,纳入3108名青少年,获取湿疹症状、严重程度及润肤剂和外用糖皮质激素治疗数据;对247名当前湿疹患者进行临床检查并使用患者导向湿疹测量(POEM)评估严重程度;从瑞典处方药登记处获取外用糖皮质激素调配信息。

主要发现

  • 10%的青少年报告过去一年有湿疹,根据BESS评分,73%为轻度、17%为中度、10%为重度。
  • 几乎所有患者使用润肤剂,55%报告使用外用糖皮质激素,性别间无显著差异。
  • 有当前湿疹症状者使用润肤剂和外用糖皮质激素的调整OR为5.95(95%CI 1.90-18.8),但更严重湿疹与轻度湿疹相比,调整OR为1.57(95%CI 0.58-4.25)。
  • 在报告湿疹的患者中,24%在过去一年有外用糖皮质激素调配记录;在中重度当前湿疹患者中,24%有强效外用糖皮质激素调配记录。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Knowledge regarding how adolescents treat their eczema is sparse. OBJECTIVES: To explore the use of emollients and topical glucocorticoids in adolescents with eczema in relation to sex and disease severity, and to study dispensing patterns of topical glucocorticoids. METHODS: Questionnaire-based data on symptoms of eczema, eczema severity and treatment with emollients and topical glucocorticoids were obtained from 3108 adolescents in the Swedish population-based birth cohort BAMSE. Severity of reported eczema was evaluated with the BAMSE Eczema Severity Score (BESS) in a questionnaire and with the Patient-Oriented Eczema Measure in clinically examined patients with current eczema (n = 247). Information on dispensed topical glucocorticoids was obtained from the Swedish Prescribed Drug Register. RESULTS: In all, 10% of the adolescents reported eczema in the preceding year: 73% mild, 17% moderate and 10% severe according to BESS. Almost all used emollients, whereas use of topical glucocorticoids was reported by 55%, with no significant difference between sexes. The likelihood of treatment with emollients and topical glucocorticoids increased when the adolescents had symptoms of current eczema [adjusted odds ratio (OR) 5·95, 95% confidence interval (CI) 1·90-18·8], but not if they had more severe eczema compared with mild eczema (adjusted OR 1·57, 95% CI 0·58-4·25). Among those with reported eczema, 24% had a topical glucocorticoid dispensed in the preceding year, and among those with moderate-to-severe current eczema 24% had a dispensed potent topical glucocorticoid. CONCLUSIONS: This population-based study indicates that adolescents with eczema are undertreated or completely untreated, even those with severe eczema.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Lundin S, Wahlgren CF, Bergström A, et al. Use of emollients and topical glucocorticoids among adolescents with eczema: data from the population-based birth cohort BAMSE. Br J Dermatol. 2018. PMID: 29478304. doi:10.1111/bjd.16484

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。